Peng Lu Sells 3,733 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 3,733 shares of Pharvaris stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $30.06, for a total value of $112,213.98. Following the transaction, the insider owned 62,350 shares of the company’s stock, valued at $1,874,241. This represents a 5.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Peng Lu also recently made the following trade(s):

• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total value of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $1.57 during midday trading on Friday, hitting $29.44. 512,191 shares of the company’s stock were exchanged, compared to its average volume of 245,049. Pharvaris N.V. has a 12 month low of $14.59 and a 12 month high of $31.14. The company’s 50 day moving average price is $27.62 and its 200 day moving average price is $26.03.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, equities research analysts predict that Pharvaris N.V. will post -3.19 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on PHVS shares. Citigroup restated a “buy” rating on shares of Pharvaris in a research note on Wednesday, April 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Wedbush boosted their price target on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Finally, Royal Bank Of Canada reduced their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $42.73.

Institutional Trading of Pharvaris

Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Pharvaris during the 4th quarter valued at $35,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pharvaris during the 3rd quarter valued at $75,000. Barclays PLC bought a new stake in shares of Pharvaris during the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pharvaris during the 4th quarter valued at $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.